NZ596820A - Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid - Google Patents

Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Info

Publication number
NZ596820A
NZ596820A NZ596820A NZ59682010A NZ596820A NZ 596820 A NZ596820 A NZ 596820A NZ 596820 A NZ596820 A NZ 596820A NZ 59682010 A NZ59682010 A NZ 59682010A NZ 596820 A NZ596820 A NZ 596820A
Authority
NZ
New Zealand
Prior art keywords
methyl
benzazepin
tetrazol
tetrahydro
trifluoromethyl
Prior art date
Application number
NZ596820A
Other languages
English (en)
Inventor
Xinchao Chen
Scott Alan Frank
David Michael Remick
Steven Wayne Pedersen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ596820(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ596820A publication Critical patent/NZ596820A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ596820A 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid NZ596820A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (1)

Publication Number Publication Date
NZ596820A true NZ596820A (en) 2013-07-26

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596820A NZ596820A (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Country Status (37)

Country Link
US (2) US8329688B2 (enExample)
EP (1) EP2448933B1 (enExample)
JP (1) JP5689875B2 (enExample)
KR (1) KR101404893B1 (enExample)
CN (1) CN102639528B (enExample)
AR (1) AR077208A1 (enExample)
AU (1) AU2010266537B2 (enExample)
BR (1) BRPI1011931A2 (enExample)
CA (1) CA2764425C (enExample)
CL (1) CL2011003263A1 (enExample)
CO (1) CO6480934A2 (enExample)
CR (1) CR20110669A (enExample)
DK (1) DK2448933T3 (enExample)
DO (1) DOP2011000405A (enExample)
EA (1) EA020600B1 (enExample)
EC (1) ECSP11011551A (enExample)
ES (1) ES2435293T3 (enExample)
GT (1) GT201100321A (enExample)
HR (1) HRP20130950T1 (enExample)
IL (1) IL216655A (enExample)
JO (1) JO2867B1 (enExample)
MA (1) MA33385B1 (enExample)
ME (1) ME01606B (enExample)
MX (1) MX2011014024A (enExample)
MY (1) MY157121A (enExample)
NZ (1) NZ596820A (enExample)
PE (1) PE20120538A1 (enExample)
PL (1) PL2448933T3 (enExample)
PT (1) PT2448933E (enExample)
RS (1) RS52988B (enExample)
SG (1) SG177413A1 (enExample)
SI (1) SI2448933T1 (enExample)
TN (1) TN2011000638A1 (enExample)
TW (1) TWI450896B (enExample)
UA (1) UA109409C2 (enExample)
WO (1) WO2011002696A1 (enExample)
ZA (1) ZA201108707B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080269284A1 (en) * 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
CN103648495A (zh) 2011-07-08 2014-03-19 诺华股份有限公司 在高甘油三酯对象中治疗动脉粥样硬化的方法
CN103958501B (zh) * 2012-07-16 2016-08-17 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
AU2014213125B2 (en) 2013-01-31 2016-06-02 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as CETP inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
WO2016016157A1 (en) 2014-07-30 2016-02-04 F. Hoffmann-La Roche Ag Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (enExample) 1970-12-15 1974-12-23
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
CA2445623A1 (en) * 2001-04-30 2002-11-07 Pfizer Products Inc. Methods for preparing cetp inhibitors
US7332514B2 (en) * 2002-08-30 2008-02-19 Japan Tobacco Inc. Dibenzylamine compound and medicinal use thereof
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) * 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
BRPI0508966A (pt) 2004-03-26 2007-08-21 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
US20080269284A1 (en) 2004-06-24 2008-10-30 Eli Lilly And Company Compounds and Methods for Treating Dyslipidemia
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
CR20110669A (es) 2012-03-16
CA2764425C (en) 2015-01-06
IL216655A (en) 2015-02-26
SI2448933T1 (sl) 2013-11-29
CO6480934A2 (es) 2012-07-16
HRP20130950T1 (hr) 2013-11-22
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
TN2011000638A1 (en) 2013-05-24
DK2448933T3 (da) 2013-10-07
AU2010266537B2 (en) 2013-04-18
UA109409C2 (ru) 2015-08-25
ES2435293T3 (es) 2013-12-18
TW201113275A (en) 2011-04-16
KR20120027426A (ko) 2012-03-21
BRPI1011931A2 (pt) 2016-04-19
PT2448933E (pt) 2013-10-29
MA33385B1 (fr) 2012-06-01
PL2448933T3 (pl) 2014-01-31
GT201100321A (es) 2012-11-15
IL216655A0 (en) 2012-02-29
DOP2011000405A (es) 2012-01-15
AR077208A1 (es) 2011-08-10
JP5689875B2 (ja) 2015-03-25
CN102639528A (zh) 2012-08-15
EP2448933B1 (en) 2013-08-28
MY157121A (en) 2016-05-13
KR101404893B1 (ko) 2014-06-20
JO2867B1 (en) 2015-03-15
CN102639528B (zh) 2014-07-16
US20100331309A1 (en) 2010-12-30
WO2011002696A1 (en) 2011-01-06
ZA201108707B (en) 2013-05-29
US8299060B2 (en) 2012-10-30
US8329688B2 (en) 2012-12-11
JP2012532106A (ja) 2012-12-13
ECSP11011551A (es) 2012-01-31
EA020600B1 (ru) 2014-12-30
US20120058990A1 (en) 2012-03-08
CA2764425A1 (en) 2011-01-06
CL2011003263A1 (es) 2012-07-27
EP2448933A1 (en) 2012-05-09
SG177413A1 (en) 2012-02-28
TWI450896B (zh) 2014-09-01
PE20120538A1 (es) 2012-05-09
EA201270099A1 (ru) 2012-05-30
AU2010266537A1 (en) 2012-02-02
MX2011014024A (es) 2012-04-20

Similar Documents

Publication Publication Date Title
TN2011000638A1 (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
MY151295A (en) Pyrimidyl indoline compound
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
MX2010009922A (es) Activadores de piridazinona glucocinasa.
WO2009066152A3 (en) Haloallylamine inhibitors of ssao/vap-1 and uses therefor
TW200745070A (en) Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and their use
TW200745069A (en) Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicaments comprising this compound and its use
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
NZ602321A (en) Compound and use for reducing uric acid comprising 2-(3-(2,6-Dimethylbenzyloxy)-4-methylphenyl)acetic acid
TW200833663A (en) Therapeutic agents
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
PH12012500622A1 (en) Compounds for the treatment of dyslipidemia and related diseases
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
GB2454615A (en) Antidiabetic azabicyclo (3.1.0) hexan compounds
MX2012001160A (es) Agonistas del receptor de esfingosina-1-fosfato.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EA201101210A1 (ru) 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-1-гидроксиэтил)-8-гидроксихинолин-2(1h)-oh для лечения легочной функции
WO2010132670A3 (en) Pentacycline compounds
PH12012501974A1 (en) Novel hypoglycemic compounds
WO2006051314A3 (en) Guanidine derivatives as inhibitors of ddah
MX2009005250A (es) Compuestos 2-alquil-indazol para el tratamiento de ciertas enfermedades relacionadas con el sistema nervioso central (cns).
WO2009053999A3 (en) Sulfoximine derivatives as factor xa inhibitors
WO2009056617A3 (en) 4,4-disubstituted piperdines as renin inhibitors
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 28 JUN 2017 BY THOMSON REUTERS

Effective date: 20140320

LAPS Patent lapsed